



## **Dawson James Securities Announces Firm Commitment Public Offering of American Depositary Shares and Nasdaq Listing for Biofrontera AG**

---

**Boca Raton, FL Feb. 16, 2018**-- Dawson James Securities, Inc. in conjunction with Biofrontera AG (Nasdaq: BFRA) Frankfurt Stock Exchange: B8F announced the pricing of a U.S. underwritten public offering of 1,215,000 American Depositary Shares, or ADSs, at an offering price of \$9.88 per ADS. Each ADS represents two of Biofrontera's ordinary shares, nominal value €1.00 per share.

Biofrontera has separately completed a concurrent preemptive rights offering of its ordinary shares pursuant to German law to its existing holders of ordinary shares, under which Biofrontera will be issuing a total of 3,399,034 ordinary shares at an offering price of €4.00 per share (or approximately \$4.96 per share, representing the same per share price as the one used in the ADS offering). These rights offering shares will trade on the Frankfurt Stock Exchange under the Company's existing listing of B8F.

The Company expects to receive aggregate gross proceeds of approximately \$12.0 million from the US offering and approximately \$16.6m from the German rights offering. The proceeds will be used to expand Biofrontera's U.S. sales and marketing organization and to fund additional clinical trials of its product Ameluz, and for general corporate purposes.

Dawson James Securities, Inc. acted as a co-manager along with The Benchmark Company, LLC and Lake Street Capital Markets. Dawson James also acted as the Qualified Independent Underwriter.

The shares described above were offered by Biofrontera AG pursuant to a registration statement previously filed with, and subsequently declared effective by the Securities and Exchange Commission ("SEC"). A final prospectus supplement relating to the offering was filed with the SEC and is available, along with the accompanying base prospectus, on the SEC's website at <http://www.sec.gov>, or by contacting Dawson James: 1 N. Federal Hwy; Suite 500, Boca Raton, FL 33432 ATTN: Prospectus Department.

### **About Biofrontera AG**

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares will commence trading on the NASDAQ Capital Market under the symbol "BFRA" on February 14, 2018, and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at [www.biofrontera.com](http://www.biofrontera.com)



**About Dawson James Securities, Inc.**

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, Maryland and New Jersey. [www.dawsonjames.com](http://www.dawsonjames.com)

**Safe Harbor Statement**

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Member FINRA/SIPC. For more information, please contact:

**Elise Stern, Managing Director, Head of Capital Markets**

[estern@dawsonjames.com](mailto:estern@dawsonjames.com)

**561-208-2926**